Ovarian Cancer Clinical Trial
ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of ISIS 5132 in treating patients who have metastatic or recurrent ovarian cancer that has not responded to previous chemotherapy.
Full Description
OBJECTIVES: I. Determine the efficacy of ISIS 5132 by evaluating objective response and duration of response in patients with recurrent ovarian epithelial cancer. II. Determine the tolerability and quantitative toxicity of ISIS 5132 in this patient population.
OUTLINE: This is a multicenter study. Patients receive ISIS 5132 IV continuously for 21 days. Courses are repeated every 28 days. Treatment continues for a maximum of 12 courses in the absence of disease progression or unacceptable toxicity. Patients with documented complete response receive an additional 2 courses. Patients with documented partial response receive an additional 4 courses. Patients are followed at 4 weeks, then every 3 months until disease relapse or progression.
PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study over 12-15 months.
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically documented ovarian epithelial cancer Metastatic and/or locally recurrent disease that is incurable with standard therapy Must have received 1 or 2 prior regimens of chemotherapy At least 1 regimen must have contained cisplatin or carboplatin Bidimensionally measurable disease Indicator lesion size must be as follows: At least 4-50 cm2 by CT scan At least 1 cm2 by chest xray At least 1 cm2 (e.g., nodules) by physical exam No abdominal adenocarcinoma of unknown origin No borderline ovarian tumor No tumor known to be of primary fallopian tube or peritoneal origin
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy: At least 12 weeks Hematopoietic: Platelet count at least 100,000/mm3 Absolute granulocyte count at least 1,500/mm3 No known bleeding disorder Hepatic: Bilirubin no greater than 2 times upper limit of normal (ULN) AST less than 5 times ULN PT/PTT normal (except when elevated due to therapeutic coumadin) Renal: Creatinine no greater than 2 times ULN Cardiovascular: No significant cardiac dysfunction Neurologic No history of significant neurologic disorder No significant psychiatric disorder Other: Not pregnant or nursing Fertile patients must use effective contraception At least 5 years since prior malignancy and no evidence of recurrence No other serious illness or medical condition No active uncontrolled infection No complete bowel obstruction
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics At least 4 weeks since prior chemotherapy No other concurrent cytotoxic therapy Endocrine therapy: Not specified Radiotherapy: Recovered from prior radiotherapy At least 4 weeks since radiotherapy to at least 20% of bone marrow Surgery: Not specified Other: As least 28 days since prior investigational agent or new anticancer therapy No concurrent therapeutic heparin No other concurrent investigational therapy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 64 Locations for this study
Duluth Minnesota, 55805, United States
New York New York, 10021, United States
Edmonton Alberta, T6G 1, Canada
Lethbridge Alberta, T1J 1, Canada
Burnaby British Columbia, V5H 4, Canada
Penticton British Columbia, V2A 3, Canada
Surrey British Columbia, V3V 1, Canada
Vancouver British Columbia, V5Z 3, Canada
Vancouver British Columbia, V5Z 4, Canada
Vancouver British Columbia, V6Z 1, Canada
Victoria British Columbia, V8R 1, Canada
Winnipeg Manitoba, R3E 0, Canada
Moncton New Brunswick, E1C 6, Canada
Moncton New Brunswick, E1C 8, Canada
Saint John New Brunswick, E2L 4, Canada
St. Johns Newfoundland and Labrador, A1B 3, Canada
Halifax Nova Scotia, B3H 1, Canada
Halifax Nova Scotia, B3H 2, Canada
Barrie Ontario, L4M 6, Canada
Brampton Ontario, L6W 2, Canada
Hamilton Ontario, L8V 5, Canada
Kingston Ontario, K7L 5, Canada
London Ontario, N6A 4, Canada
Mississauga Ontario, L5B 1, Canada
Mississauga Ontario, L5M 2, Canada
Newmarket Ontario, L3Y 2, Canada
North York Ontario, M2E 1, Canada
Oshawa Ontario, L1G 2, Canada
Ottawa Ontario, K1H 8, Canada
Ottawa Ontario, K1Y 4, Canada
Peterborough Ontario, K9H 7, Canada
Sault Sainte Marie Ontario, P6B 1, Canada
Scarborough Ontario, M1P 2, Canada
St. Catharines Ontario, L2R 5, Canada
Sudbury Ontario, P3E 5, Canada
Thunder Bay Ontario, P7A 7, Canada
Toronto Ontario, M4C 3, Canada
Toronto Ontario, M4N 3, Canada
Toronto Ontario, M5B 1, Canada
Toronto Ontario, M5G 1, Canada
Toronto Ontario, M5G 2, Canada
Toronto Ontario, M5G 2, Canada
Toronto Ontario, M5S 1, Canada
Toronto Ontario, M6R 1, Canada
Weston Ontario, M9N 1, Canada
Windsor Ontario, N8W 2, Canada
Charlottetown Prince Edward Island, C1A 8, Canada
Fleurimont Quebec, J1H 5, Canada
Joliette Quebec, J6E 6, Canada
Montreal Quebec, H1T 2, Canada
Montreal Quebec, H2W 1, Canada
Montreal Quebec, H2W 1, Canada
Montreal Quebec, H2W-W, Canada
Montreal Quebec, H2X 3, Canada
Montreal Quebec, H3A 1, Canada
Montreal Quebec, H3G 1, Canada
Montreal Quebec, H3T 1, Canada
Montreal Quebec, H4A 3, Canada
Montreal Quebec, H4J 1, Canada
Quebec City Quebec, G1R 2, Canada
Quebec City Quebec, G1S 4, Canada
Saint Jean-Sur-Richelieu Quebec, J3A 1, Canada
Ste-Foy Quebec, G1V 4, Canada
Regina Saskatchewan, S4T 7, Canada
Saskatoon Saskatchewan, S7N 4, Canada
Southampton England, SO14 , United Kingdom
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.